CN108004315A - Appraisal procedure for Alzheimer's disease risk - Google Patents
Appraisal procedure for Alzheimer's disease risk Download PDFInfo
- Publication number
- CN108004315A CN108004315A CN201711399846.7A CN201711399846A CN108004315A CN 108004315 A CN108004315 A CN 108004315A CN 201711399846 A CN201711399846 A CN 201711399846A CN 108004315 A CN108004315 A CN 108004315A
- Authority
- CN
- China
- Prior art keywords
- sites
- detection
- tet
- alzheimer
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to biological gene detection field, disclose a kind of appraisal procedure for Alzheimer's disease risk, DNA is extracted from human body cell, PCR reactions are carried out to APOE genetic fragments as template using the dissociative DNA of extraction and the base type of two SNP sites of rs429358 and rs7412 of APOE genes is identified by fluoroscopic examination, and the Alzheimer's disease risk of receipts detection crowd is assessed by the result of fluoroscopic examination.The advantage of the invention is that, solve the problems, such as that existing detection means is costly, the risk of substantial amounts of examined crowd can be predicted with relatively low cost and expense, for next step medical treatment detection or social developmental plan provides low cost, effectively, there is higher application value.
Description
Technical field
The present invention relates to biological gene detection field, more particularly to a kind of commenting for Alzheimer's disease risk
Estimate method, human body gene detection and risk assessment are combined.
Background technology
Alzheimer's disease (Alzheimer ' s Disease, abbreviation AD), Chinese former name " senile dementia ", is
A kind of nerve cell death due to brain and caused by nerve degenerative diseases, occurred in over-65s crowd.According to U.S.
The statistics of state, the ratio with AD is about 4% in 65~69 years old crowd, and in the elderly population more than 85 years old, the ratio
Example is then up to 36%.Meanwhile over-65s old man it is lethal the reason in, AD rankings the 9th.The whole America there are about 4,000,000 AD patients.And
China, patient populations are up to 9,000,000.The AD patient populations in the whole world are up to 2100~35,000,000.Expect the year two thousand thirty, global AD patient
Quantity may increase to 70,000,000.With age, the risk for suffering from AD is consequently increased.
AD is a kind of gradual process.The symptom of early stage may be mistakenly considered caused by old
It is forgetful so as to ignored.With the progressively development of the state of an illness, ability of learning and memory, cognition judgement and many days of patient
Often the basic capacity of activity is all gradually degenerated, while may occur in which the symptoms such as disposition change, behavior difficulty.In diseased late period, AD can
Patient is caused to lose intelligence, final death.Average each AD patient makes a definite diagnosis that follow-up to renew the time living be about 8 years.In the U.S., except medicine
Outside expense, the expense only nursed to AD patient is just up to 100,000,000,000 dollars.Averagely for the various of each AD patient
Expense is about 174,000 dollars.So high expense is all extremely white elephant to personal and society.
Gradual due to AD, sufferers themselves and its family members often do not recognize to have shown to suffer from its morbidity early stage
The symptom of disease, and usually it is mistakenly considered the normal phenomenon that is producing because of old.And when patient has shown obvious abnormality disease
When shape starts to see a doctor, the detection in terms of behaviouristics is typically carried out, and with the brain of definite patient the methods of combination clinical detection
Whether nerve has exception.And at this moment AD has had evolved to certain phase, best occasion for the treatment has often been had already passed by.It is so early
The examination of phase is extremely important.And traditional clinical testing procedure includes expensive position emissron tomography (abbreviation PET), or carry out
The lumbar puncture of pain carries out cerebrospinal fluid sampling etc..It is such detection no matter in economic capability or body it is physiologically tested
Person is often difficult to bear.And the clinical detection precision of early stage is not high, possible mistaken diagnosis.So carry out a kind of convenient and efficient
And cheap initial in vitro molecular level detection method is just very necessary.
The method of traditional live body DNA detections APOE is genomic DNA in extraction cerebrospinal fluid or haemocyte etc..It is such as existing
The method with blood DNA identification APOE that technology proposes, is to extract the genomic DNA in haemocyte as detection method, at the same time
This method can not know the somatic variation information in brain tissue source.
Wide concerned cell free DNA (cell free DNA, abbreviation cfDNA) in recent years, in lesion tissue
The somatic variation accumulated in apoptosis or non-viable non-apoptotic cell, with elderly patients' brain tissue is closely related.Current liquid Biopsy
Operation can not depended on, non-invasively obtaining human body fluid (including blood plasma and other various body fluid, such as urine, saliva, sweat, chest
Hydrops etc.) in derive from brain tissue micro metabolic DNA fragment, so as to carry out disease correlation body cell base in brain tissue for us
Because variation detection provides more more options space and great convenience.Detected different from traditional genomic DNA, this technology can
Reflection patient's body lesion situation in real time, so that the assessment of progression of the disease situation is dynamically carried out according to the state of an illness in real time, and and
When formulate corresponding therapeutic scheme.So being detected compared to traditional genomic DNA, Alzheimers are carried out using cfDNA
The diagnosis of disease has big advantage in clinical practice.
The content of the invention
The present invention in the prior art for alzheimer's disease testing cost it is excessive the shortcomings that, there is provided Yi Zhongyong
In the appraisal procedure of Alzheimer's disease risk, there is provided a kind of appraisal procedure that can be applied in different age group,
This method can be assessed with regard to the examined individual risk in specific crowd, so as to instruct the examined individual
Next step medical treatment detection.
To achieve the above object, the present invention can take following technical proposals：
A kind of appraisal procedure for Alzheimer's disease risk, including step in detail below：From human body cell
Middle extraction DNA, the DNA come from human body fluid and are located at extracellular dissociative DNA；Using the dissociative DNA of extraction as template
PCR reactions are carried out to APOE genetic fragments and two SNP of rs429358 and rs7412 of APOE genes are identified by fluoroscopic examination
The base type in site, PCR reactions use the probe with FAM and TET fluorescence radiation groups；After PCR reactions start, detection
Fluorescence results；Risk is excessive risk when fluoroscopic examination result is following result：1) rs429358 sites FAM and TET is glimmering
The detection of light luminophore has reaction, and rs7412 sites FAM and the detection of TET fluorescence radiations group have reaction；2)
Rs429358 sites FAM and the detection of TET fluorescence radiations group have reaction, and rs7412 sites only TET fluorescence radiations group is examined
Survey has reaction；3) rs429358 sites only TET fluorescence radiations group detection has reaction, rs7412 sites only TET fluorescence radiations base
Group's detection has reaction.
Further, as a kind of optional scheme, in embodiments herein, when rs429358 sites, only TET is glimmering
The detection of light luminophore has reaction, and the only TET fluorescence radiations group detection of rs7412 sites has reaction, then it is pole to evaluate risk
It is high.
Further, as a kind of optional scheme, in embodiments herein, it is used in PCR reactions
Rs429358 sites amplification primer sequence and probe sequence be：
rs429358F：5’-ACGGCTGTCCAAGGAGCTGC-3’
rs429358R：5’-AGGCGCACCCGCAGCTCCTC-3’
prob-1T：5’-FAM-AGGACGTGTGCGGCCGCCTG-MGB Eclipse-3’
prob-1C：5’-TET-AGGACGTGCGCGGCCGCCTG-MGB Eclipse-3’
Further, as a kind of optional scheme, in embodiments herein, it is used for rs7412 in PCR reactions
Site amplification primer sequence and probe sequence be：
rs7412F：5’-TGCGGGTGCGCCTCGCCTCCC-3’
rs7412R：5’-AGGCGCTCGCGGATGGCGCTG-3’
prob-2T：5’-FAM-CAGAAGTGCCTGGCAGTGTA-MGB Eclipse-3’
prob-2C：5’-TET-CAGAAGCGCCTGGCAGTGTA-MGB Eclipse-3’
Further, as a kind of optional scheme, in embodiments herein, the human body fluid includes peripheral blood
Liquid, saliva, cerebrospinal fluid, chest hydrops and urine.
The present invention has following notable technique effect：
Relatively low cost can be used to complete to comment for the alzheimer's disease risk of big quantity particular range crowd
Estimate prediction.
Brief description of the drawings
Fig. 1 is PCR fluoroscopic examination result schematic diagrams.
Embodiment
With reference to embodiment, the present invention is described in further detail.
Embodiment 1
A kind of appraisal procedure for Alzheimer's disease risk, be mainly useful for the larger crowd of quantity into
Capable Alzheimer's disease risk is deleted and classified, including step in detail below：Extracted from human body cell
DNA, the DNA come from human body fluid and are located at extracellular dissociative DNA；It is template to APOE using the dissociative DNA of extraction
Genetic fragment carries out PCR reactions and two SNP sites of rs429358 and rs7412 of APOE genes is identified by fluoroscopic examination
Base type, PCR reactions use the probe with FAM and TET fluorescence radiation groups；After PCR reactions start, fluorescence knot is detected
Fruit；Risk is excessive risk when fluoroscopic examination result is following result：1) rs429358 sites FAM and TET fluorescence radiation
Group detection has reaction, and rs7412 sites FAM and the detection of TET fluorescence radiations group have reaction；2) rs429358 sites
The detection of FAM and TET fluorescence radiations group has reaction, and the only TET fluorescence radiations group detection of rs7412 sites has reaction；3)
The only TET fluorescence radiations group detection of rs429358 sites has reaction, and the only TET fluorescence radiations group detection of rs7412 sites has anti-
Should.The above method is only used for risk assessment, in particular for the crowd of classification to(for) big quantity, when above-mentioned detection knot
Fruit not definitely indicates whether detected person is diseased, it is necessary to carry out further detection in order to determine if illness.This
Outside, the methods of risk assessment in the application also contemplates the diseased probability of overall patient groups, the economy of diagnosis and is examined
The age of survey crowd.In addition, the age of onset in the application for risk is preset as average 76 one full year of life, therefore for difference
It is only to predict for the examined people of age bracket, does not can confirm that whether it can diseased and illness age.
Further, when rs429358 sites, only TET fluorescence radiations group detection has reaction, and rs7412 sites only TET is glimmering
The detection of light luminophore has reaction, then it is high to evaluate risk.In the case, the diseased age of prediction falls to average
68 one full year of life, it is contemplated that carrying crowd's quantity of gene, therefore, needs the risk to Alzheimer's disease in such cases
Carry out additional attention or carry out the medicine detection of early stage.
Further, the primer sequence of rs429358 sites amplification is used in PCR reactions and probe sequence is：
rs429358F：5’-ACGGCTGTCCAAGGAGCTGC-3’
rs429358R：5’-AGGCGCACCCGCAGCTCCTC-3’
It is primer sequence above.
prob-1T：5’-FAM-AGGACGTGTGCGGCCGCCTG-MGB Eclipse-3’
prob-1C：5’-TET-AGGACGTGCGCGGCCGCCTG-MGB Eclipse-3’
It is probe sequence above, probe carries FAM or TET fluorescence radiations group and MGB Eclipse fluorescent quenchings
Group, it is ensured that when PCR reactions do not carry out, PCR system does not send fluorescence；After PCR reactions proceed by, PCR product
Combined with fluorescence probe and begin to send out fluorescence, and can be detected and record with sufficiently strong luminous intensity.
Further, the primer sequence of rs7412 sites amplification is used in PCR reactions and probe sequence is：
rs7412F：5’-TGCGGGTGCGCCTCGCCTCCC-3’
rs7412R：5’-AGGCGCTCGCGGATGGCGCTG-3’
It is primer sequence above.
prob-2T：5’-FAM-CAGAAGTGCCTGGCAGTGTA-MGB Eclipse-3’
prob-2C：5’-TET-CAGAAGCGCCTGGCAGTGTA-MGB Eclipse-3’
It is probe sequence above.
Above-mentioned primer and probe are directed to specific site and use, and above-mentioned primer and probe can be by commercially available
Obtain.
Further, the human body fluid includes peripheral blood, saliva, cerebrospinal fluid, chest hydrops and urine.
In addition, what the extracellular DNA that embodiments herein further comprises in the above-mentioned body fluid by human peripheral was extracted
Step：
200 μ l blood plasma are taken into the centrifuge tube of 2ml, add 20 μ l Proteinase K solution, is vortexed and mixes；Add 200
The buffer solution GB of μ l, gently overturns and mixes, and 56 DEG C are incubated 10 minutes, and shake sample frequently.Brief centrifugation is to remove in tube cover
The drop of wall；Add the ethanol (100%) of 200 μ l precoolings.Gently overturn mix sample, room temperature place 5 minutes, brief centrifugation with
Remove the drop of cap wall；Previous step resulting solution is added in an adsorption column CR2 (adsorption column is put into collecting pipe),
12,000rpm (~13,400 × g) are centrifuged 30 seconds, abandon waste liquid, adsorption column CR2 is put back in collecting pipe；Add into adsorption column CR2
Enter 500 μ l buffer solutions GD, 12,000rpm (~13,400 × g) centrifugation 30 seconds, abandon waste liquid, adsorption column CR2 is put back into collecting pipe
In；600 μ l rinsing liquids PW, 12,000rpm (~13,400 × g) centrifugation 30 seconds is added into adsorption column CR2, waste liquid is abandoned, will inhale
Attached column CR2 is put back in collecting pipe, repeats this step；12,000rpm (~13,400 × g) are centrifuged 2 minutes, outwell waste liquid.It will inhale
Attached column CR2 is placed in room temperature and places 2-5 minutes, thoroughly to dry rinsing liquid remaining in sorbing material；Adsorption column CR2 is transferred to one
In a clean centrifuge tube, 20-50 μ l elution buffer TB are vacantly added dropwise to adsorbed film centre position, room temperature is placed 2-5 minutes,
12,000rpm (~13,400 × g) are centrifuged 2 minutes, solution are collected into centrifuge tube, up to cfDNA.
Further, PCR reactions are carried out to cfDNA obtained above, comprised the following steps that：In above-mentioned cfDNA, take
5ng is template, and primer combines every kind of each 0.9uM (final concentration), the every kind of each 0.2uM (final concentration) of probe combinations, 2 ×
MasterMix 5ul, with ddH2O polishings cumulative volume to 10ul, PCR reaction conditions are 95 DEG C, 10 minutes, and with 95 DEG C 15 seconds,
60 DEG C of frequencies of 30 seconds carry out 30-40 circulation.The fluorescence results recorded in PCR reaction process are as shown in Figure 1.
In short, the foregoing is merely presently preferred embodiments of the present invention, all equalizations made according to scope of the present invention patent
Change and modification, should all belong to the covering scope of patent of the present invention.
Claims (5)
1. a kind of appraisal procedure for Alzheimer's disease risk, it is characterised in that including step in detail below：From
DNA is extracted in human body cell, the DNA comes from human body fluid and is located at extracellular dissociative DNA；With the free of extraction
DNA be template to APOE genetic fragments carry out PCR reactions and by fluoroscopic examination identify APOE genes rs429358 and
The base type of two SNP sites of rs7412, PCR reactions use the probe with FAM and TET fluorescence radiation groups；PCR is anti-
After should starting, fluorescence results are detected；Risk is excessive risk when fluoroscopic examination result is following result：1) rs429358 sites
The detection of FAM and TET fluorescence radiations group has reaction, and rs7412 sites FAM and the detection of TET fluorescence radiations group have anti-
Should；2) rs429358 sites FAM and TET fluorescence radiation group detection has reaction, rs7412 sites only TET fluorescence radiations base
Group's detection has reaction；3) rs429358 sites only TET fluorescence radiations group detection has reaction, and rs7412 sites only TET fluorescence is sent out
The detection of light group has reaction.
2. the appraisal procedure according to claim 1 for Alzheimer's disease risk, it is characterised in that when
The only TET fluorescence radiations group detection of rs429358 sites has reaction, and the only TET fluorescence radiations group detection of rs7412 sites has anti-
Should, then it is high to evaluate risk.
3. the appraisal procedure according to claim 1 for Alzheimer's disease risk, it is characterised in that
Primer sequence and probe sequence in PCR reactions for the amplification of rs429358 sites are：
rs429358F：5’-ACGGCTGTCCAAGGAGCTGC-3’
rs429358R：5’-AGGCGCACCCGCAGCTCCTC-3’
prob-1T：5’-FAM-AGGACGTGTGCGGCCGCCTG-MGB Eclipse-3’
prob-1C：5’-TET-AGGACGTGCGCGGCCGCCTG-MGB Eclipse-3’.
4. the appraisal procedure according to claim 1 for Alzheimer's disease risk, it is characterised in that
Primer sequence and probe sequence in PCR reactions for the amplification of rs7412 sites are：
rs7412F：5’-TGCGGGTGCGCCTCGCCTCCC-3’
rs7412R：5’-AGGCGCTCGCGGATGGCGCTG-3’
prob-2T：5’-FAM-CAGAAGTGCCTGGCAGTGTA-MGB Eclipse-3’
prob-2C：5’-TET-CAGAAGCGCCTGGCAGTGTA-MGB Eclipse-3’.
5. the appraisal procedure according to claim 1 for Alzheimer's disease risk, it is characterised in that described
Human body fluid includes peripheral blood, saliva, cerebrospinal fluid, chest hydrops and urine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711399846.7A CN108004315A (en) | 2017-12-22 | 2017-12-22 | Appraisal procedure for Alzheimer's disease risk |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711399846.7A CN108004315A (en) | 2017-12-22 | 2017-12-22 | Appraisal procedure for Alzheimer's disease risk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108004315A true CN108004315A (en) | 2018-05-08 |
Family
ID=62060552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711399846.7A Pending CN108004315A (en) | 2017-12-22 | 2017-12-22 | Appraisal procedure for Alzheimer's disease risk |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108004315A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114410774A (en) * | 2022-02-17 | 2022-04-29 | 杭州怡健医疗科技有限公司 | Risk assessment method applied to Alzheimer's disease |
| CN114736963A (en) * | 2022-05-25 | 2022-07-12 | 首都医科大学宣武医院 | Substance combination for predicting Alzheimer disease onset risk, kit and application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101240318A (en) * | 2007-02-06 | 2008-08-13 | 上海主健生物工程有限公司 | Kit for detecting senile dementia susceptible inheritance risk |
| CN101608229A (en) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | Kit for genetic detection of gout |
| CN101748189A (en) * | 2008-12-22 | 2010-06-23 | 上海基康生物技术有限公司 | Senile dementia related locus detection method |
| CN102676669A (en) * | 2012-05-04 | 2012-09-19 | 周宏灏 | Kit and method for detecting apolipoprotein E (ApoE) gene polymorphisms by means of pyro sequencing method |
| CN104073548A (en) * | 2013-03-27 | 2014-10-01 | 沈迪 | Mononucleotide polymorphism detection method based on melting curves and kit thereof |
| RU2600874C2 (en) * | 2014-04-09 | 2016-10-27 | Федеральное государственное бюджетное учреждение науки Российской академии наук Институт молекулярной биологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) | Set of oligonucleotide primers and probes for genetic typing of polymorphous dna loci associated with a risk of progression of sporadic form of alzheimer's disease in russian populations |
| CN107099602A (en) * | 2017-05-27 | 2017-08-29 | 宁波美晶医疗技术有限公司 | It is a kind of at the same detect statins metabolic gene multisite mutation kit |
| CN107447030A (en) * | 2017-09-20 | 2017-12-08 | 苏州康吉诊断试剂有限公司 | The kit of Alzheimer's disease APOE genetic tests |
-
2017
- 2017-12-22 CN CN201711399846.7A patent/CN108004315A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101240318A (en) * | 2007-02-06 | 2008-08-13 | 上海主健生物工程有限公司 | Kit for detecting senile dementia susceptible inheritance risk |
| CN101608229A (en) * | 2008-06-20 | 2009-12-23 | 上海主健生物工程有限公司 | Kit for genetic detection of gout |
| CN101748189A (en) * | 2008-12-22 | 2010-06-23 | 上海基康生物技术有限公司 | Senile dementia related locus detection method |
| CN102676669A (en) * | 2012-05-04 | 2012-09-19 | 周宏灏 | Kit and method for detecting apolipoprotein E (ApoE) gene polymorphisms by means of pyro sequencing method |
| CN104073548A (en) * | 2013-03-27 | 2014-10-01 | 沈迪 | Mononucleotide polymorphism detection method based on melting curves and kit thereof |
| RU2600874C2 (en) * | 2014-04-09 | 2016-10-27 | Федеральное государственное бюджетное учреждение науки Российской академии наук Институт молекулярной биологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) | Set of oligonucleotide primers and probes for genetic typing of polymorphous dna loci associated with a risk of progression of sporadic form of alzheimer's disease in russian populations |
| CN107099602A (en) * | 2017-05-27 | 2017-08-29 | 宁波美晶医疗技术有限公司 | It is a kind of at the same detect statins metabolic gene multisite mutation kit |
| CN107447030A (en) * | 2017-09-20 | 2017-12-08 | 苏州康吉诊断试剂有限公司 | The kit of Alzheimer's disease APOE genetic tests |
Non-Patent Citations (2)
| Title |
|---|
| 何驳奇: "中国人群阿尔茨海默病ApoE基因的Meta分析及TaqMan-TAMRA探针基因分型方法的建立", 《中国优秀硕士学位论文全文数据库》 * |
| 崔红丽: "中国人群ApoE基因多态性与阿尔茨海默病相关性的Meta分析", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114410774A (en) * | 2022-02-17 | 2022-04-29 | 杭州怡健医疗科技有限公司 | Risk assessment method applied to Alzheimer's disease |
| CN114736963A (en) * | 2022-05-25 | 2022-07-12 | 首都医科大学宣武医院 | Substance combination for predicting Alzheimer disease onset risk, kit and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Prideaux et al. | Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease | |
| CN110484624B (en) | Gastric cancer biomarker based on peripheral blood and detection method and application thereof | |
| CN105603101B (en) | Detect application of the system of 8 miRNA expression quantity in diagnosis or auxiliary diagnosis of hepatoma product is prepared | |
| CN104004840B (en) | Test kit for early screening Yu diagnosis of prostate cancer | |
| JP2020516231A (en) | Methods for determining the status of colorectal cancer in an individual | |
| CN108949997A (en) | A kind of lung cancer detection marker and diagnostic kit | |
| CN112609015A (en) | Microbial marker for predicting colorectal cancer risk and application thereof | |
| CN114277143B (en) | Application of exosomes ARPC5, CDA and the like in lung cancer diagnosis | |
| CN106591487A (en) | Serum microRNA diagnostic marker for osteoportic fractures in old people and diagnostic kit thereof | |
| CN108004315A (en) | Appraisal procedure for Alzheimer's disease risk | |
| CN115287351A (en) | Application of exosomes miR-106b-3p and miR-125a-5p in lung cancer diagnosis | |
| CN105296661A (en) | Kit for diagnosing tuberculosis by detecting free nucleic acid and application of kit | |
| JP2021531832A (en) | Liquid biopsy Early diagnosis and post-treatment monitoring of breast cancer using multiple oncogene biomarkers | |
| CN109266733B (en) | Autistic intestinal flora virulence factor gene and application thereof | |
| CN112708686A (en) | Application of intestinal flora in nerve injury detection | |
| KR102018171B1 (en) | Breast cancer detection kit using saliva and method using the same | |
| CN114941030B (en) | SNP marker for gastric cancer auxiliary diagnosis and application thereof | |
| CN104004824A (en) | Quantitative determination kit for free DNA in serum of breast cancer patient, and application method thereof | |
| CN113817837B (en) | Free DNA sequence derived from echinococcus granulosus and application thereof | |
| RU2447447C1 (en) | Method for prediction of developing metachronous colon cancer | |
| Mathias et al. | LIQUID BIOPSY-A COMPLEMENTARY APPROACH TO TISSUE BIOPSY | |
| US11807908B2 (en) | Genetic markers used for identifying benign and malignant pulmonary micro-nodules and the application thereof | |
| CN115820857A (en) | Kit for identifying precancerous lesions of stomach cancer and diagnosing stomach cancer | |
| Asandei et al. | Clinical Study of Saliva Metabolomics and Microbiomics in Respiratory Diseases | |
| CN113817853A (en) | Application of intestinal microorganisms as marker of mild traumatic brain trauma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180508 |
|
| WD01 | Invention patent application deemed withdrawn after publication |